
-
NRX Pharmaceuticals NasdaqCM:NRXP NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder, and chronic pain. Its lead drug candidates include NRX-101, an oral, fixed dosed combination of D-cycloserine and lurasidone for suicidal treatment-resistant bipolar depression in patients with sub-acute suicidal ideation and behavior in phase 2 trial; and NRX-100, a preservative-free formulation of ketamine for intravenous infusion and for the treatment of suicidal depression. The company has a license agreement with Alvogen, Inc. and Lotus Pharmaceutical Co. Ltd.; Apkarian Technologies; development and license agreement with Glytech, LLC; and Sarah Herzog Memorial Hospital. NRx Pharmaceuticals, Inc. was founded in 2015 and is based in Wilmington, Delaware.
Location: 1201 Orange Street, Wilmington, DE, 19801, United States | Website: https://www.nrxpharma.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
45.41M
Cash
1.443M
Avg Qtr Burn
-2.659M
Short % of Float
8.56%
Insider Ownership
16.78%
Institutional Own.
13.13%
Qtr Updated
12/31/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
HTX-100 (ketamine) Details Acute Suicidal Ideation and Behavior, Bipolar depression | NDA Submission | |
NRX-100 (IV ketamine) Details Suicidal Depression | NDA Submission | |
NRX-101 Details Treatment Resistant Depression, Bipolar depression | NDA Submission | |
NRX-101 Details Chronic pain | Phase 2 Data readout | |
NRX-101 Details Post-traumatic stress disorder | Phase 2 Initiation | |
Failed Discontinued | ||
BRILIFE Details COVID-19 | Failed Discontinued |